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T
he consequence of Parkinson’s 
disease (PD) is well described: 
a progressive movement 
disorder that, whilst responding to 
symptomatic therapy, chronically 
disables its sufferers and adds an 
enormous economic burden in an 
aging society. We have some clues to 
the process underlying the disease 
from the snapshot provided by 
postmortem studies of diseased brains. 
Groups of neurons in speciﬁ  c brain 
regions are lost, notably those that 
produce dopamine in a part of the 
midbrain called the substantia nigra. 
Those neurons that do survive to the 
end of the disease course contain 
accumulations of proteins and lipids 
within their cytoplasm. Named after 
their discoverer, these “Lewy bodies” 
are one piece of evidence that protein 
aggregation is related to the ongoing 
disease process. 
In contrast, the causes of PD are 
poorly deﬁ  ned except in those rare 
variant forms that are clearly genetic. 
Several families have been described 
where PD-like syndromes are inherited 
in either a dominant or recessive 
fashion, and four of the underlying 
genes have been identiﬁ  ed. The 
precise relationships between these 
different syndromes are complex and 
are the subject of some controversy. 
For example, it is not clear whether 
all the genetic diseases given PARK 
nomenclature have Lewy bodies and 
should be considered “true” PD—the 
term parkinsonism is preferred for 
these syndromes (Hardy and Langston 
2004). For the purposes of this primer, 
I will concentrate on the molecular 
biology of the genes linked to PD 
rather than disease etiology. However, 
my assumption is that symptoms of the 
disease are a reﬂ  ection of neuronal 
dysfunction, and that in the disease 
state the balance between damage and 
survival tips in the direction of cell loss. 
Whilst dominant mutations overwhelm 
the ability of cells to survive, recessive 
mutations result in the absence of 
protective proteins and make the 
neuron grow weaker. 
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Aggregation of α-Synuclein in 
Neurodegeneration
On the detrimental side of the cell 
survival equation is the PD gene that 
was discovered ﬁ  rst, α-synuclein. The 
synaptic protein encoded by this gene, 
α-synuclein, is prone to aggregation, 
and, as is the case for other aggregating 
proteins, mutations in α-synuclein are 
associated with dominantly inherited 
disease. Related to this, α-synuclein is 
a major protein component of Lewy 
bodies. The phenotype of patients with 
α-synuclein mutations varies from PD 
to a more diffuse Lewy body disease 
in which pathology is detected in the 
cerebral cortex and other areas of the 
brain. Mutations in α-synuclein include 
three point mutations (A30P, E46K, 
and A53T) and multiplication of the 
wild-type (normal) gene. All of these 
mutations increase the tendency of α-
synuclein to aggregate, suggesting that 
disease is a consequence of protein 
aggregation. An interesting example is 
the triplication of the wild-type gene: 
toxicity and aggregation can both be 
driven by increased expression and 
are thus qualitative, not quantitative, 
effects (Singleton et al. 2003). The 
fact that the wild-type protein can 
aggregate suggests that the process 
is fundamentally similar for both 
inherited and sporadic PD in which 
wild-type α-synuclein is also present in 
Lewy bodies. Several commentators 
have suggested that non-genetic risk 
factors may also promote damage via 
their effects on (wild-type) α-synuclein 
conformation or aggregation (e.g., 
Di Monte 2003). This reinforces the 
notion that α-synuclein is central to 
the pathogenesis of both sporadic and 
familial PD.
There is some controversy about 
the exact nature of the toxic species 
produced by α-synuclein, as one 
point mutation (A30P) behaves 
differently from the others. Instead of 
forming ﬁ  brils, which are insoluble, 
high-molecular-weight species, A30P 
forms relatively soluble, partially 
aggregated species (Conway et al. 
2000). These intermediate-sized 
protein aggregates are referred to as 
oligomers or protoﬁ  brils. Some authors 
have argued that since A30P causes 
disease, oligomers/protoﬁ  brils are the 
authentic toxic species. It is generally 
assumed that ﬁ  brils are the form of α-
synuclein deposited into Lewy bodies, 
but whether Lewy bodies damage cells 
is controversial. One possibility is that 
by sequestering α-synuclein into this 
insoluble body and compartmentalizing 
the potentially toxic species away from 
possible targets in the cytoplasm, the 
Lewy body represents an attempt of 
the cell to protect itself (Olanow et al. 
2004).
Whether the Lewy body is damaging 
or neuroprotective, there are clearly 
several possible targets for toxic 
α-synuclein within the cell. For 
example, aggregated α-synuclein can 
permeabilize cellular membranes and 
thus might damage organelles (Volles 
and Lansbury 2003). Mitochondrial 
function and synaptic transmission 
may be especially affected, and both 
of these can secondarily increase 
oxidative stress within the cytosol 
(Greenamyre and Hastings 2004). 
When overexpressed, mutant α-
synuclein can inhibit the proteasome 
(Petrucelli et al. 2002), a multiprotein 
complex that degrades many unwanted 
or inappropriate proteins in cells. 
Mutant forms of α-synuclein also 
inhibit chaperone-mediated autophagy, 
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Figure 1. Molecules That Cause or Prevent Parkinson’s Disease  
(A) shows a simpliﬁ  ed, linear view of the aggregation pathway of α-synuclein (in blue). 
The monomer of α-synuclein is a natively unfolded protein with several repeats, shown 
by dark bars on the monomer. The protein has an innate tendency to aggregate with 
other molecules of α-synuclein, ﬁ  rst into oligomers (also known as protoﬁ  brils), then 
into ﬁ  brils. It is the ﬁ  brillar forms of α-synuclein that are deposited into the classic 
pathological structures of PD, Lewy bodies. There are several studies that suggest that the 
oligomeric intermediates are the major toxic species, although this is not certain. 
(B) shows the recessive mutations associated with parkinsonism and their possible 
relationships to subcellular targets, either mitochondria (left) or the proteasome (right). 
Insults to either of these can cause cellular damage and may interact. For example, 
proteasome inhibitors can cause mitochondrial damage, which can be antagonized by 
PINK1. Parkin can promote the turnover of proteasomal substrates, and DJ-1 can prevent 
mitochondrial damage. 
Quite whether (B) relates to (A) is not clear, but recent results with DJ-1 imply that DJ-
1 has chaperone activity towards oligomers of α-synuclein (see text). Although there 
is much to be done to resolve the order of these events, it is likely that, either alone or 
in concert, damage to multiple cellular pathways leads to neuronal dysfunction and, 
eventually, cell death.PLoS Biology  |  www.plosbiology.org 1719
another important protein turnover 
pathway that involves lysosomes 
(Cuervo et al. 2004). Between these 
two effects, it is likely that cells with 
aggregated α-synuclein will become less 
able to handle damaged or misfolded 
proteins. It is also possible that other 
cellular processes that we have not yet 
identiﬁ  ed are affected by the presence 
of this protein that has such an innate 
tendency to aggregate.
Presumably, neurons require α-
synuclein for their normal function 
and thus cannot simply dispense with 
this protein that has toxic properties, 
although mice in which the α-synuclein 
gene is knocked out have no obvious 
deﬁ  cits (see Dauer and Przedborski 
[2003] for discussion).
Parkin, DJ-1, and PINK1 in 
Neuroprotection
Evolution has provided cells with 
many ways to protect themselves. As we 
will see, mutations that cause recessive 
diseases result in the loss of these 
neuroprotective functions. The genes 
involved in recessive parkinsonism 
are, in order of discovery, parkin, 
DJ-1, and PINK1. The three protein 
products of these genes all have 
different functions, thus implicating 
several different cellular functions 
in neuroprotection. Parkin is an E3 
ubiquitin–protein ligase, promoting 
the addition of ubiquitin to target 
proteins prior to their degradation by 
the proteasome. The identiﬁ  cation of 
parkin’s function was facilitated by the 
observation that the protein contains 
a RING ﬁ  nger (Zhang et al. 2000), a 
common motif amongst this class of 
E3 enzymes. Several parkin substrates 
have been proposed, and at least two 
are damaging to neurons if they are 
allowed to accumulate (Dong et al. 
2003; Yang et al. 2003). Therefore, our 
best evidence to date indicates that 
parkin beneﬁ  ts neurons by removing 
proteins that might otherwise damage 
the cell. In fact, expression of parkin 
is neuroprotective in a number of 
contexts, and there is even evidence 
for a beneﬁ  cial effect of this E3 ligase 
on mitochondrial function (Shen and 
Cookson 2004).
Data on PINK1 are limited, but 
the protein contains two motifs that 
indicate its likely cellular role. At 
the amino-terminus of PINK1 is a 
mitochondrial-targeting sequence, 
and mitochondrial localization has 
been conﬁ  rmed in the one study 
published to date (Valente et al. 
2004). Most of the rest of PINK1 
is a Serine/Threonine protein 
kinase domain, followed by a short 
carboxy-terminal region of unclear 
signiﬁ  cance. The substrates of PINK1 
have not yet been identiﬁ  ed, but 
presumably phosphorylation of these 
substrates controls some critical 
function for neuronal survival. In 
their paper, Valente and colleagues 
show that PINK1 decreases damage to 
mitochondria induced by proteasome 
inhibition, but a recessive mutant 
PINK1 is unable to protect cells.
The discussion of protein functions 
gets more complicated in the case of 
DJ-1. Unlike parkin or PINK1, there are 
no motifs within DJ-1 that hint strongly 
at a single function. Instead, DJ-1 is 
a member of a large superfamily of 
genes with several different functions 
across species (Bandyopadhyay 
and Cookson 2004). These include 
proteases in thermophilic bacteria, 
transcription factors, and chaperones 
that promote protein refolding. Several 
research groups have published data 
in support of DJ-1 having one or more 
of these activities, including the report, 
published in this issue of PLoS Biology, 
that DJ-1 is a molecular chaperone that 
regulates α-synuclein, among other 
molecules (Shendelman et al. 2004). 
It is not yet ﬁ  rmly established which 
activity of DJ-1 is most relevant to 
recessive parkinsonism. The important 
function of DJ-1 might be unrelated to 
any of the above activities. For example, 
there are several roles of this protein 
in modulation of transcriptional 
responses, which may be critical in 
maintaining neuronal viability (Bonifati 
et al. 2003 and references therein)
DJ-1 is also known to be responsive 
to oxidative conditions, under which 
cysteine residues are oxidized to 
form cysteine-sulﬁ  nic acids. There is 
some discussion about which cysteine 
residue is oxidized; the most likely 
is cysteine 106, which is present in 
a nucleophile elbow in the protein. 
We have suggested that modifying 
this residue precludes DJ-1 oxidation 
under mild conditions and also blocks 
the neuroprotective activity of DJ-1 
against mitochondrial toxicity (Canet-
Aviles et al. 2004). Therefore, whatever 
the function of DJ-1, it seems to be 
related to oxidation. In support of 
this idea, cells with DJ-1 knocked out 
show increased sensitivity to oxidative 
stress (Yokota et al. 2003). Another 
study published in this issue of PLoS 
Biology shows that dopamine neurons 
differentiated from embryonic stem 
cells lacking functional DJ-1 are 
especially sensitive to oxidative stress 
(Martinat et al. 2004). 
This discussion indicates that 
the genes responsible for recessive 
parkinsonism all have different 
functions but are all, in a broad sense, 
neuroprotective. A very difﬁ  cult 
question to answer is whether this has 
anything to do with α-synuclein. We 
have shown that parkin can mitigate 
the toxicity of mutant α-synuclein 
(Petrucelli et al. 2002). Although there 
are reports that a proportion of α-
synuclein is a parkin substrate (Shimura 
et al. 2001), most of the protein is not 
degraded by the ubiquitin-proteasome 
system. Recent evidence points, instead, 
to an important role of the lysosome, 
the other major pathway within cells 
for degrading unwanted proteins, in 
clearing α-synuclein (Cuervo et al. 
2004). On balance, therefore, there 
is no direct evidence that parkin 
controls α-synuclein toxicity by an 
effect on protein levels within the 
cell. Furthermore, parkin does not 
just prevent α-synuclein toxicity: it is 
beneﬁ  cial against several other stresses 
(discussed in Shen and Cookson 2004), 
leading to the possibility that this 
protein protects neurons against more 
than just the processes implicated in PD.   
It has also been suggested that 
DJ-1 can prevent the accumulation 
of aggregated α-synuclein and that 
cysteine 53 is critical for this activity 
(Shendelman et al. 2004). However, 
DJ-1 is not just a chaperone for α-
synuclein; it can also promote refolding 
of citrate synthase, glutathione 
transferase, and neuroﬁ  lament light. 
Other research groups have reported 
similar ﬁ  ndings (Olzmann et al. 
2004), although there are differences 
between these studies in which cysteine 
residues are thought to be required 
for DJ-1 function. Given that there 
are some differences in these results, 
further clariﬁ  cation of the role for 
DJ-1 in α-synuclein-mediated toxicity 
is needed. More generally, we have to 
bear in mind that whether recessive 
parkinsonism has anything to do with 
α-synuclein is still an open question. 
What is clear is that some neurons 
rely on parkin, DJ-1, or PINK1 to protect 
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themselves against the many stresses 
that they face. However, mutations in 
these genes do not cause generalized 
neurodegeneration; in fact, they 
tend to be more restricted and less 
progressive than, for example, α-
synuclein mutations. This suggests, 
at least to my mind, that recessive 
mutations indicate something about 
the neurons that are damaged in these 
disorders. Why is this of more than 
academic importance? Perhaps by 
identifying the proximal events that 
are sufﬁ  cient to cause a speciﬁ  c set of 
neurons to degenerate, we might begin 
to design therapies that address the 
underlying degeneration in PD and not 
just the consequences.  
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